Home

 

Update - Participant Closeout Visits and Final Results Presentation!

All closeout visits for participants randomized to ISCHEMIA and ISCHEMIA-CKD should be completed by June 30th, 2019. The final results presentation is expected to follow later this year at AHA in November. More information will follow as the date approaches.

The ISCHEMIA Baseline Characteristics Paper has been Published

The ISCHEMIA Baseline Characteristics and Risk Profiles Paper was published in the Journal of the American Medical Association on February 27, 2019.  The paper can be found online HERE.

ISCHEMIA Design Paper Published in July 2018

The ISCHEMIA Design Paper was published in the American Heart Journal July 2018 edition (Vol. 201) on pages 124-135. A PDF copy of the paper can be found HERE.

 

What is the ISCHEMIA Study? 

  • An international comparative effectiveness study
  • The purpose of ISCHEMIA is to determine the best way to manage stable ischemic heart disease.
  • Patients with moderate or severe ischemia, with or without stress imaging, may be eligible for participation.

If you are a physician and would like more information, please visit the For Physicians section.

If you are a patient and would like to learn more about the ISCHEMIA study, please e-mail ischemia@nyulangone.org

Why is the ISCHEMIA Study Important?

Ischemic heart disease (IHD) is the leading cause of death and disability worldwide and affects 17,600,000 Americans, resulting in about 450,000 deaths in the United States annually. Globally, 7.2 million deaths are caused by IHD each year.

Medical therapy (medication and lifestyle changes) should always be used to treat IHD. Many doctors routinely use an invasive approach in addition to medical therapy to treat IHD; however, it is not known if this approach is better than medical therapy alone as the initial treatment of patients with stable ischemic heart disease (SIHD), moderate to severe ischemia. ISCHEMIA is designed to find the answer.

 

Total Number of Participants Randomized to the ISCHEMIA Trial

There are 5,179 participants (pts) randomized worldwide in the ISCHEMIA study. Click here to see the randomizations by country.

Congratulations To Our Top Sites!

Site name Region Study Team Total Rands

Government Medical College

India

PI: Dr. Sajeev & Dr. Nair SC: Anand, Raj, Ravindran, & Vijayan Sunitha

208 pts

Northwick Park Hospital- Royal Brompton Hospital, London

U.K.

PI: Senior Co-PI: Elghamaz SC: Kinsey, Kavalakkat, Howard, Bucaj, & Encarnado

202 pts

Sri Jayadeva Institute of Cardiovascular Sciences and Research, Banglore-Karnataka India PI: Dr. Manjunath & Dr. Moorthy SC: Nataraj, Kumbar, & Nayak

149 pts

Atlanta V.A. Medical Center

USA

PI: Dr. Mavromatis SC: Lee, Patel, & Doan

139 pts

Heart Instituto do Coracao - University of Sao Paulo

Brazil

PI: Dr. Hueb SC: Takiuti

127 pts

Coronary and Structural Heart Diseases Department, Institute of Cardiology, Warsaw

Poland

PI: Prof. Demkow SC: Chojnacka, Frelek, & Pracon 127 pts
Hospital Universitario La Paz Spain PI: Dr. Lopez-Sendon SC: Valbuena, Castro, La Paz Mediavilla, Albaladejo & Fernandez-Figares  118 pts
Bakulev Scientific Center for Cardiovascular Surgery Russia PI: Dr. Bockeria SC: O. Bockeria, Aripova & Kudzoeva  113 pts

Complejo Hospitalario Universitario de A Coruna

Spain

PI: Dr. Peteiro SC: Blanco & Garcia Gonzalez

 112 pts

Guangdong General Hospital

China PI: Dr. Chen SC: Dong, He, Xia, Yang, & Zhong  102 pts